Zelegent, Inc.

We've closed our Series A equity financing, from a syndicate of 12 investors. The lead investor was our new worldwide selling, marketing, and distribution partner, ALPHAEON Corp. http://www.zelegent.com/alphaeon-and-zelegent-announce-exc/

Zelegent Chairman Krespi is brought back up to the podium at the European ORL-HNS conference in Prague to answer more questions about the novel procedure for snoring cessation.

Zelegent Chairman Yosef Krespi, MD presenting the company's first clinical trial outcomes at the European ORL-HNS conference in Prague, Czech Republic on June 8, 2015.

Zelegent CEO Alex Arrow explaining the mission of the company, to develop a medical device that overcomes the limitations of currently-available anti-snoring interventions.

Zelegent, Inc. Pilot Study Results Show Significant Improvement in All Study Endpoints http://www.zelegent.com/prague-results.html